Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB) | Zendy

Caryn M. Upton | Zendy; Chanel I Steele | Zendy; Gary Maartens | Zendy; Andreas H. Diacon | Zendy; Lubbe Wiesner | Zendy; Kelly E. Dooley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)

Author(s) -

Caryn M. Upton,

Chanel I Steele,

Gary Maartens,

Andreas H. Diacon,

Lubbe Wiesner,

Kelly E. Dooley

Publication year - 2022

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkac067

Subject(s) - bedaquiline , medicine , cerebrospinal fluid , pharmacokinetics , tuberculosis , tuberculous meningitis , lumbar puncture , pharmacology , pathology , mycobacterium tuberculosis

With current treatment options most patients with CNS TB develop severe disability or die. Drug-resistant tuberculous meningitis is nearly uniformly fatal. Novel treatment strategies are needed. Bedaquiline, a potent anti-TB drug, has been reported to be absent from CSF in a single report.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research